» Articles » PMID: 37273753

CRP‑1 Promotes the Malignant Behavior of Hepatocellular Carcinoma Cells Via Activating Epithelial‑mesenchymal Transition and Wnt/β‑catenin Signaling

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2023 Jun 5
PMID 37273753
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. It has been reported that cysteine rich protein 1 (CRP-1) is dysregulated in several types of human cancer; however, its role in HCC is poorly understood. Therefore, the current study aimed to investigate the role of CRP-1 in HCC. Western blotting and reverse transcription-quantitative PCR results showed that CRP-1 was upregulated in HCC cell lines. Furthermore, for experiments, CRP-1 was knocked down and overexpressed in the HCC cell lines Hep 3B2.1-7 and BEL-7405, respectively. c-Myc and proliferating cell nuclear antigen upregulation, and cleaved caspase 3 and poly(ADP-ribose) polymerase downregulation suggested that CRP-1 silencing could inhibit the proliferation and colony-forming ability of HCC cells, and induce apoptosis. In addition, CRP-1 overexpression promoted the malignant behavior of HCC cells and induced epithelial-mesenchymal transition (EMT), as verified by E-cadherin downregulation, and N-cadherin and vimentin upregulation. Additionally, CRP-1 overexpression promoted the nuclear translocation of β-catenin, and activated the expression of cyclin D1 and matrix metalloproteinase-7. Furthermore, inhibition of Wnt/β-catenin signaling, following cell treatment with XAV-939, an inhibitor of the Wnt/β-catenin signaling pathway, abrogated the effects of CRP-1 on enhancing the proliferation and migration of HCC cells. These findings indicated that the regulatory effect of CRP-1 on HCC cells could be mediated by the Wnt/β-catenin signaling pathway. Overall, CRP-1 could promote the proliferation and migration of HCC cell lines, partially via promoting EMT and activating the Wnt/β-catenin signaling pathway.

Citing Articles

TMEM209 promotes hepatocellular carcinoma progression by activating the Wnt/β-catenin signaling pathway through KPNB1 stabilization.

Fang H, Shi X, Gao J, Yan Z, Wang Y, Chen Y Cell Death Discov. 2024; 10(1):438.

PMID: 39414762 PMC: 11484822. DOI: 10.1038/s41420-024-02207-9.


Wnt/β-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target.

Zhao Z, Cui T, Wei F, Zhou Z, Sun Y, Gao C Front Oncol. 2024; 14:1367364.

PMID: 38634048 PMC: 11022604. DOI: 10.3389/fonc.2024.1367364.

References
1.
Ringelhan M, Pfister D, OConnor T, Pikarsky E, Heikenwalder M . The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19(3):222-232. DOI: 10.1038/s41590-018-0044-z. View

2.
He G, Zhu H, Yao Y, Chai H, Wang Y, Zhao W . Cysteine-rich intestinal protein 1 silencing alleviates the migration and invasive capability enhancement induced by excessive zinc supplementation in colorectal cancer cells. Am J Transl Res. 2019; 11(6):3578-3588. PMC: 6614615. View

3.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

4.
Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

5.
Asselin E, Mills G, Tsang B . XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 2001; 61(5):1862-8. View